Inorganic Growth Through Alliances and M&A
First written in FY2023. 8 of 13 entries say "Advanced", first in FY2024-Q2. Latest entry: 2026-10-14.
15 other companies' latest entry also says "Advanced".
- FY2026-H1WorsenedAnnual report
「株式会社アドメディカ, formerly our consolidated subsidiary, had been in liquidation after the Board of Directors resolved to dissolve it at a meeting held on 20 November 2025. As the distribution of its residual assets was completed in May 2026 and the substantive liquidation procedures were completed, it has been excluded from the scope of consolidation from the current interim consolidated accounting period.」
For アドメディカ, which was acquired as part of the group's M&A-driven growth initiatives, the completion of its dissolution and liquidation procedures and its exclusion from the scope of consolidation have been confirmed following its failure to meet earnings expectations and the recognition of an impairment loss. - FY2025-H1AchievedAnnual report
「At a meeting of the Board of Directors held on 14 January 2025, we resolved to acquire 95.01% of the total issued shares of 株式会社ポラリファイ and make it a subsidiary, entered into a share transfer agreement on the same date, and acquired the shares on 27 March 2025.」
The planned acquisition of ポラリファイ, announced in FY2024, was completed on 27 March 2025 through the acquisition of 95.01% of its issued shares. - FY2024AdvancedAnnual report
「In January 2025, we announced that 株式会社ポラリファイ would become a subsidiary.」
Following アドメディカ's inclusion as a subsidiary and its impact on consolidated results, the company announced the acquisition of 株式会社ポラリファイ as a subsidiary, scheduled for 27 March 2025, with a planned acquisition of 95.01% of its voting rights, advancing its use of M&A to the next transaction. - FY2024-Q2AdvancedAnnual report
「During the first quarter consolidated accounting period, アドメディカ became a consolidated subsidiary after we acquired 50.1% of its total issued shares. As 31 December 2023 was treated as the acquisition date and the difference from the quarterly consolidated balance sheet date did not exceed 3 months, only the balance sheet was consolidated for the first quarter consolidated accounting period, while the income statement was also consolidated from the second quarter consolidated accounting period.」
Following its inclusion as a consolidated subsidiary through the acquisition of 50.1% of アドメディカ, the income statement was also consolidated from the second quarter consolidated accounting period, bringing the acquisition's effects into the consolidated results. - FY2024-Q1AchievedAnnual report
「On 29 February 2024, we acquired 50.1% of the issued shares of 株式会社アドメディカ (hereinafter, "アドメディカ") and completed its inclusion as a consolidated subsidiary.」
The planned acquisition of アドメディカ, announced in FY2023, was completed through the acquisition of 50.1% of its issued shares and its inclusion as a consolidated subsidiary. The plan to create synergies, including developing new advertising products and web media by combining the existing business platform with the group's solutions, remains in place. - FY2023First statedAnnual report
「We are pursuing alliances and M&A as means of achieving inorganic growth. As part of this strategy, we announced in January 2024 that 株式会社アドメディカ would become a subsidiary. We will continue to pursue alliances and M&A while maintaining financial soundness.」
The company explicitly identified the use of alliances and M&A as the fourth pillar of its growth strategy and planned to make アドメディカ a subsidiary by acquiring 50.1% of its voting rights in February 2024.